Management of pharmaceutical resources for the primary prevention of coronary heart disease in Catalonia (Spain) based on efficiency and equity

Disease Management and Health Outcomes

Volumn 9, Issue 9, 2001, Pages 495-506

  Plans Rubio P ^a  

^a Evaluation Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; MEVINOLIN; NICOTINE; NIFEDIPINE; PROPRANOLOL;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; HEALTH CARE DISTRIBUTION; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; SMOKING CESSATION; SPAIN;

EID: 0034796240     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200109090-00004     Document Type: Article

References (29)

1. Disease management: What is it?
2. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease
3. Cost-effectiveness of cardiovascular prevention programs in Spain
4. Foundations of cost-effectiveness analysis for health and medical practices
5. QALY and the equity-efficiency trade-off
6. Cost-effectiveness/utility analysis. Do current decision rules lead us to where we want to be?
7. Cost-effectiveness analysis in a setting of budget constraints. Is it equitable?
8. Second Report of the National Cholesterol Education Program on detection, evaluation, and treatment of high blood cholesterol in adults
9. Task force report. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Join Task Force of European and other Societies on coronary prevention
10. Report of the Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure
11. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics
12. Foundations of cost-effectiveness analysis for health and medical practices
13. On the decision rules of cost-effectiveness analysis
14. Principles of cost-effectiveness resource allocation in health care organizations
15. Epidemiology of cardiovascular disease risk factors in Catalonia (Spain)
16. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions
17. Competing practice guidelines: Using cost-effectiveness analysis to make optimal decisions
18. The measurement of individual utility and social welfare
19. The effect of managed care on prescription drug costs and benefits
20. The effects of co-payments and generic substitution on the use and costs of prescription drugs
21. The effect of drug co-payments on utilization and costs of pharmaceuticals in a health maintenance organization